Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-711 as Monotherapy or in Combination With Budigalimab in Advanced Squamous Tumors
NCT07241039Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Primary completion
- Apr 2029
- Countries
- 4
01
Overview
Phase 1, open-label trial of ABBV-711 in squamous cell carcinoma (SCC) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events and Best Overall Response. Started Nov 2025; status: recruiting.
02
Drugs
ABBV-711
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT07241039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241039.